Gene therapy approval for Duchenne muscular dystrophy: a European perspective
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For treatment of the musculature, Elevidys has been approved by the US Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labour and Welfare, based on dystrophin restoration, without proof of functional benefit in the North Star Ambulatory Assessment test in placebo-controlled trials (Mendell et al., 2025; reviewed in Jolly et al., 2025).”
From Understanding Duchenne muscular dystrophy-associated brain pathology (2025) · cites this paper as Jolly et al., 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Mendell, J. R., Sahenk, Z., Lehman, K., Nease, C., Lowes, L. P., Miller, N. F., Iammarino, M. A., Alfano, L. N., Nicholl, A., Al-Zaidy, S., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1484 · Cited by 405
Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Self-citationAdeno-Associated Virus Integration: Virus versus Vector
Smith, R. H. (2008) · Gene Therapy · doi:10.1038/gt.2008.55 · Cited by 178
Research works printed but not linked: 9
- Shin, 2013, Microdystrophin ameliorates muscular dystrophy in the canine model of Duchenne muscular dystrophy, Mol Ther, 21, 750, 10.1038/mt.2012.283 · DOI · Paper page
- Mendell, 2023, A phase 2 clinical trial evaluating the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in patients with Duchenne muscular dystrophy (DMD) (S48.004), Neurology, 100, 10.1212/WNL.0000000000202973 · doi:10.1212/wnl.0000000000202973
- Mendell, 2025, AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial, Nat Med, 31, 332, 10.1038/s41591-024-03304-z · DOI · Paper page
- Muntoni, 2024, CIFFREO, a phase 3, randomized, double-blind, placebo-controlled study of fordadistrogene movaparvovec (FM) in ambulatory participants with Duchenne muscular dystrophy (DMD), Neuromuscul Disord, 43
- Ayyar Gupta, 2023, Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy, PLoS One, 18, 10.1371/journal.pone.0283669 · DOI
- Muntoni, 2019, Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy, PLoS One, 14, 10.1371/journal.pone.0221097 · DOI
- Stimpson, 2024, Quantifying variability in motor function in Duchenne muscular dystrophy: UK centiles for the North Star Ambulatory Assessment, 10 m walk run velocity and rise from floor velocity in GC treated boys, J Neuromuscul Dis, 11, 153, 10.3233/JND-230159 · doi:10.3233/jnd-230159
- Relaix, 2021, Perspectives on skeletal muscle stem cells, Nat Commun, 12, 692, 10.1038/s41467-020-20760-6 · DOI · Paper page
- Horton, 2022, A systematic review of adeno-associated virus gene therapies in neurology: the need for consistent safety monitoring of a promising treatment, J Neurol Neurosurg Psychiatry, 93, 1276
Cited by
Understanding Duchenne muscular dystrophy-associated brain pathology
Verhaeg, M. A. T., Govaarts, R., & van Putten, M. (2025) · Disease Models & Mechanisms · doi:10.1242/dmm.052302 · Cited by 5
Metadata
- Authors
- Jolly, H., Aartsma-Rus, A., Bertini, E., De Waele, L., Haberlova, J., Klein, A., Niks, E., & Servais, L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2025-05
- Volume
- 405
- Issue
- 10489
- Pages
- 1572-1573
- ISSN
- 0140-6736
- Cited by
- 11
- References
- 4
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene therapy approval for Duchenne muscular dystrophy: a European perspective. https://app.cochat.ai/papers/10.1016/s0140-6736(25)00717-2
- The paper
- Jolly, H., Aartsma-Rus, A., Bertini, E., De Waele, L., Haberlova, J., Klein, A., Niks, E., & Servais, L. (2025). Gene therapy approval for Duchenne muscular dystrophy: a European perspective. The Lancet. https://doi.org/10.1016/s0140-6736(25)00717-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.